HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer

Marisa Mariani, Mark McHugh, Marco Petrillo, Steven Sieber, Shiquan He, Mirko Andreoli, Zheyang Wu, Paul Fiedler, Giovanni Scambia, Shohreh Shahabi, Cristiano Ferlini*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

Ovarian cancer is the most lethal gynecologic malignancy. Recently, NACT (Neo Adjuvant Chemotherapy) has been tested as alternative approach for the management of ovarian cancer patients. A biological predictor helpful in selecting patients for NACT would be desirable. This study was aimed at identifying actionable mechanisms of resistance to NACT. Expression of a panel of microRNAs was screened in a discovery set of 85 patients. Analysis of the potential targets was conducted in the same RNAs by calculating significant correlations between microRNAs and genes. Quantitative fluorescent immunohistochemistry was employed in a validation set of 109 patients. MiR-193a-5p was significantly overexpressed in the NACT setting. Analysis of its potential targets demonstrated that this microRNA is also significantly correlated with HGF and MET genes. Analysis of protein expression in samples taken before and after NACT demonstrated that both HGF and c-Met are increased after NACT. Patients who relapse shortly after NACT exhibited the highest relative basal expression of both HGF and c-Met, while the opposite phenomenon was observed in the best responders. Mir-193a-5p, HGF and c-Met expression may help select eligible patients for this modality of treatment. Moreover, inhibitors of this pathway may improve the efficacy of NACT.

Original languageEnglish (US)
Pages (from-to)4855-4867
Number of pages13
JournalOncotarget
Volume5
Issue number13
DOIs
StatePublished - 2014

Keywords

  • HGF
  • Met
  • Ovarian cancer

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer'. Together they form a unique fingerprint.

Cite this